Indiana University School of Medicine, Indianapolis, IN, USA.
Clin Transl Sci. 2011 Jun;4(3):204-9. doi: 10.1111/j.1752-8062.2011.00280.x.
To address provider struggles to provide evidence-based, rational drug therapy to pregnant women, this third Conference was convened to highlight the current progress and research in the field. Speakers from academic centers, industry, and governmental institutions spoke about: the Food and Drug Administration's role in pregnancy pharmacology and the new labeling initiative; drug registries in pregnancy; the pharmacist's role in medication use in pregnancy; therapeutic areas such as preterm labor, gestational diabetes, nausea and vomiting in pregnancy, and hypertension; breast-feeding and medications; ethical challenges for consent in pregnancy drug studies; the potential for cord blood banks; and concerns about the fetus when studying drugs in pregnancy. The Conference highlighted several areas of collaboration within the current Obstetrics Pharmacology Research Units Network and hoped to educate providers, researchers, and agencies with the common goal to improve the ability to safely and effectively use individualized pharmacotherapy in pregnancy.
为了解决医疗服务提供者在为孕妇提供基于证据的合理药物治疗方面的困难,本次第三届会议的召开旨在强调该领域当前的进展和研究。来自学术中心、行业和政府机构的演讲者就以下方面进行了讨论:食品和药物管理局在妊娠药理学和新标签倡议方面的作用;妊娠药物注册;药剂师在孕妇用药方面的作用;早产、妊娠糖尿病、妊娠恶心和呕吐以及高血压等治疗领域;母乳喂养和药物;妊娠药物研究中同意的伦理挑战;脐血库的潜力;以及在妊娠期间研究药物时对胎儿的担忧。会议重点介绍了当前产科药理学研究单位网络内的几个合作领域,并希望为有共同目标的提供者、研究人员和机构提供教育,以提高在妊娠期间安全有效地使用个体化药物治疗的能力。